1. Home
  2. VERA vs BGSI Comparison

VERA vs BGSI Comparison

Compare VERA & BGSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vera Therapeutics Inc.

VERA

Vera Therapeutics Inc.

HOLD

Current Price

$37.22

Market Cap

3.0B

Sector

Health Care

ML Signal

HOLD

BGSI

Boyd Group Services Inc.

N/A

Current Price

$102.90

Market Cap

3.5B

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
VERA
BGSI
Founded
2016
1990
Country
United States
Canada
Employees
N/A
13449
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.0B
3.5B
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
VERA
BGSI
Price
$37.22
$102.90
Analyst Decision
Strong Buy
Buy
Analyst Count
10
1
Target Price
$81.30
$157.00
AVG Volume (30 Days)
2.5M
18.8K
Earning Date
05-06-2026
05-13-2026
Dividend Yield
N/A
0.38%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$35.07
Revenue Next Year
$472.48
$8.01
P/E Ratio
N/A
$231.07
Revenue Growth
N/A
N/A
52 Week Low
$19.07
$88.97
52 Week High
$56.05
$183.10

Technical Indicators

Market Signals
Indicator
VERA
BGSI
Relative Strength Index (RSI) 42.34 59.02
Support Level $32.48 $93.83
Resistance Level $38.59 $110.36
Average True Range (ATR) 2.75 3.19
MACD -0.78 1.36
Stochastic Oscillator 11.67 83.70

Price Performance

Historical Comparison
VERA
BGSI

About VERA Vera Therapeutics Inc.

Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.

About BGSI Boyd Group Services Inc.

Boyd Group Services Inc is engaged in operating non-franchised collision repair centers in North America. The Company's primary line of business is automotive collision and glass repair and related services, with the majority of revenues relating to this group of similar services. This line of business operates in Canada and the U.S. and both regions exhibit similar long-term economic characteristics. he Company is also a retail auto glass operator in the United States, under the trade names Gerber Collision & Glass, Glass America, Auto Glass Service, Auto Glass Authority. The company has majority of its sales from USA.

Share on Social Networks: